These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 33389509

  • 1. C3 glomerulopathy and atypical hemolytic uremic syndrome: an updated review of the literature on alternative complement pathway disorders.
    Turkmen K, Baloglu I, Ozer H.
    Int Urol Nephrol; 2021 Oct; 53(10):2067-2080. PubMed ID: 33389509
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
    Sethi S, Fervenza FC.
    Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
    [Abstract] [Full Text] [Related]

  • 4. Clinical guides for atypical hemolytic uremic syndrome in Japan.
    Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S, Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan.
    Clin Exp Nephrol; 2016 Aug; 20(4):536-543. PubMed ID: 27422619
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?
    Ankawi GA, Clark WF.
    BMJ Case Rep; 2017 Aug 10; 2017():. PubMed ID: 28798244
    [Abstract] [Full Text] [Related]

  • 7. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment.
    Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A.
    Ther Apher Dial; 2019 Feb 10; 23(1):4-21. PubMed ID: 30294946
    [Abstract] [Full Text] [Related]

  • 8. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
    Aradottir SS, Kristoffersson AC, Roumenina LT, Bjerre A, Kashioulis P, Palsson R, Karpman D.
    Front Immunol; 2021 Feb 10; 12():690821. PubMed ID: 34177949
    [Abstract] [Full Text] [Related]

  • 9. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
    Michels MAHM, van de Kar NCAJ, Volokhina EB, van den Heuvel BLPWJ.
    Methods Mol Biol; 2021 Feb 10; 2227():83-96. PubMed ID: 33847933
    [Abstract] [Full Text] [Related]

  • 10. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.
    Haydock L, Garneau AP, Tremblay L, Yen HY, Gao H, Harrisson R, Isenring P.
    J Mol Med (Berl); 2022 Feb 10; 100(2):269-284. PubMed ID: 34714369
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical guides for atypical hemolytic uremic syndrome in Japan.
    Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S, Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan.
    Pediatr Int; 2016 Jul 10; 58(7):549-55. PubMed ID: 27460397
    [Abstract] [Full Text] [Related]

  • 14. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ, Conference Participants.
    Kidney Int; 2017 Mar 10; 91(3):539-551. PubMed ID: 27989322
    [Abstract] [Full Text] [Related]

  • 15. Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015.
    Noris M, Remuzzi G.
    Am J Kidney Dis; 2015 Aug 10; 66(2):359-75. PubMed ID: 26032627
    [No Abstract] [Full Text] [Related]

  • 16. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
    Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ.
    J Immunol; 2018 Apr 01; 200(7):2464-2478. PubMed ID: 29500241
    [Abstract] [Full Text] [Related]

  • 17. A Guide for Adult Nephrologists and Hematologists to Managing Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy in Teens Transitioning to Young Adults.
    Riedl Khursigara M, Matsuda-Abedini M, Radhakrishnan S, Hladunewich MA, Lemaire M, Teoh CW, Noone D, Licht C.
    Adv Chronic Kidney Dis; 2022 May 01; 29(3):231-242. PubMed ID: 36084970
    [Abstract] [Full Text] [Related]

  • 18. Management of pediatric hemolytic uremic syndrome.
    Gülhan B, Özaltın F, Fidan K, Özçakar ZB, Söylemezoğlu O.
    Turk J Pediatr; 2024 May 01; 66(1):1-16. PubMed ID: 38523374
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.